{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040929","form_type":"8-K","ticker":"SYBX","cik":"0001527599","company_name":"SYNLOGIC, INC.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.202028+00:00","generated_at":"2026-06-11T17:20:34.596599+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Synlogic reports Q2 2023 net loss of $15.0M; Phase 3 PKU trial initiated","bullets":["Net loss $15.0M ($0.21/sh) vs $15.8M ($0.22/sh) in Q2 2022; cash $46.3M.","Revenue $35K from Roche collaboration, down from $152K year-over-year.","R&D expenses $11.8M; G&A $3.9M, both slightly lower than prior year.","Initiated pivotal Phase 3 Synpheny-3 trial for labafenogene marselecobac (SYNB1934) in PKU (n=150).","FDA granted Fast Track designation; WHO approved INN 'labafenogene marselecobac'."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040929","json":"https://secwatch.observer/filing/0000950170-23-040929.json","markdown":"https://secwatch.observer/filing/0000950170-23-040929.md","text":"https://secwatch.observer/filing/0000950170-23-040929.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023040929/0000950170-23-040929-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023040929/sybx-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:20:34.596599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"70907cd27ade51768684602bf5fe6e423a5c58e6","claim":"SYNLOGIC, INC. reported the quarter ended June 30, 2023 results: revenue $35 thousand, net income consolidated net loss of $15.0 million, or $0.21 per share.","evidence_excerpt":"2023 Financial Results and Financial Outlook As of June 30, 2023, Synlogic had cash and cash equivalents of $46.3 million. Revenue for the three months ended June 30, 2023 was $35 thousand compared to $152 thousand for the corresponding period in 2022. Revenue in both periods was primarily associated with the ongoing research collaboration with Roche for the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527599/000095017023040929/0000950170-23-040929-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$35 thousand"},{"label":"Net income","value":"consolidated net loss of $15.0 million, or $0.21 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}